Dr. Robert Knight has been the Medical Director at TriSalus since August 2023. In this position, he plays a central role in the execution of our SD-101 clinical trials and device focused studies. Dr. Knight also supports the design of clinical protocols in addition to data collection, reporting and interpretation.
Dr. Knight is board certified in internal medicine, hematology, and oncology. During his pharmaceutical career he participated in and led clinical trials in Clinical Development in phase I through phase III in both large and small companies. These include clinical programs that have led to Health Authority approvals in the US, EU, Australia, Japan, and China and include such agents as pamidronate (Aredia), zoledronate (Zometa), irinotecan (Camptosar), thalidomide (Thalomid), lenalidomide (Aredia), and enasidenib (IDHIFA). In addition, his experience includes leading CAR-T cell trials in hematologic and solid tumors, including studies with liver metastases using PEDD.
Dr. Knight received his B.S. degree from the United States Military Academy at West Point, N.Y. and his M.D. from the State University of New York Downstate (Brooklyn, N.Y.).